Reslizumab (Synonyms: Sch 55700) |
رقم الكتالوجGC39430 |
Reslizumab (Sch 55700) عبارة عن أجسام مضادة أحادية النسيلة متوافقة مع البشر تستهدف الإنترلوكين -5 (IL-5) لعلاج الربو الحمضي
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 241473-69-8
Sample solution is provided at 25 µL, 10mM.
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab inhibits IL-5-dependent cell proliferation, with an IC50 value of approximately 91.1pM. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively[1][2].
[1]. Liddament M, et al. Higher Binding Affinity and in vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab. Allergy Asthma Immunol Res. 2019 Mar;11(2):291-298. [2]. PÉrez de Llano LA, et al. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab. Allergy. 2019 Sep 4.
Average Rating: 5
(Based on Reviews and 28 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *